Pharmaceutical and Health Care Industry Weekly Report: Outstanding Performance of the Pharmaceutical Sector, Assisted Reproductive Technology Included in Beijing Medical Insurance Reimbursement_Oriental Fortune Network

Last week (0221-0225), the Shanghai Composite Index fell by 1.1%, and the SW Biomedical Index rose by 1.7%, ranking sixth among the 28 Shenwan primary industries. The top three performances of the biomedical sector are:Chemical materialsMedicines (+4.5%), Chemicals (+2.2%),traditional Chinese medicine(+0.6%).The top three gainers areChengda Pharmaceutical(+66.04%)、Zhenong Co., Ltd.(+55.35%)、Kangzhi Pharmaceutical(+54.75%); the top three decliners areGuobang Medicine(-9.55%)、Haixiang Pharmaceutical(-14.79%), *ST Haiyi (-18.50%).

Several companies in the pharmaceutical sectorperformanceNewsletters performed well.As of the last closing day of last week (0225), 118 companies have released their 2021 financial resultsnet profitYear-on-year growth rate:Nuohe Zhiyuan(515.74%)、Aohua Endoscopy(211.34%)、Zhifei Biological(208.88)、Olin Bio(206.18%)、Wantai Bio(197.83%)、Oriental creatures(184.80%)、Nanotech(158.75%)、Medici(117.93%)、Haier Bio(114.81%)、Key Kai Technology(106.50%) and other 12 companies achieved double growth.

16 assisted reproductive technologies (IVF) are covered by Beijing medical insurance. On February 21, the Beijing Medical Insurance Bureau and others issued the “Regulations on Regulations and Adjustments”medical serviceNotice of Price Items (Beijing Medical Insurance Fa? 2022? No. 7), which includes 16 assisted reproductive technologies such as intrauterine insemination, embryo transfer, and optimal sperm treatment, which are common in outpatient clinics, into the scope of medical insurance Category A reimbursement. We believe that the pilot program of IVF in Beijing is expected to be gradually included in the national medical insurance. IVF medical serviceSome prices are not expected to be reduced, and there may be a possibility of price reductions for IVF-related consumables.

Measures such as medical insurance covering IVF and encouraging third births can help increase the overall willingness to have children.

Haitong Pharma’s portfolio performance in February 2022.Zhifei Biological、Xinhua Medical、Yifeng Pharmacy、Tongrentang、Aier Ophthalmology、Kanghua Biology、Mindray Medical、Tigermed、WuXi AppTec、Porton shares(names not listed in order). In February, the portfolio has risen by an average of 5.7% so far, while the All Index Pharmaceuticals has risen by 3.5% in the same period, and the portfolio has outperformed the Pharmaceutical Index by 2.2pct. The top three monthly portfolio gains are in order.Zhifei Biological(19.4%)、Xinhua Medical(15.1%)、Aier Ophthalmology(9.6%)。

risk warning. The advancement of policies is not up to expectations, the risk of medical insurance cost control has increased, the risk of valuation fluctuations, and the continued development of the epidemic has brought the risk of global economic shocks.

(Article Source:Haitong Securities）

Article source: Haitong Securities

Responsible editor: 10

Original title: Pharmaceutical and Health Care Industry Weekly Report: The performance of the pharmaceutical sector is eye-catching. Assisted reproductive technology is included in the scope of Beijing medical insurance reimbursement